New hope for indian men with advanced prostate cancer: enzalutamide under study
NCT ID NCT03641560
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and effectiveness of enzalutamide (Xtandi) in 52 Indian men with metastatic castration-resistant prostate cancer that had worsened after chemotherapy. Participants took enzalutamide daily while continuing hormone therapy. The main goal was to see how many experienced side effects, and researchers also measured PSA levels to gauge response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enzalutamide (Xtandi)
What this could lead to
If successful, this could confirm that enzalutamide is safe and effective for Indian patients with advanced prostate cancer, offering a treatment option after chemotherapy.
What could go wrong
This is a small, single-arm study with no placebo group, so results may not be generalizable. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site IN00001
Pune, India
-
Site IN00002
Ahmedabad, India
-
Site IN00003
Nashik, India
-
Site IN00004
Hubli, India
-
Site IN00007
Nashik, India
-
Site IN00008
Kolkata, India
-
Site IN00010
New Delhi, India
-
Site IN00011
Surat, India